Support 100 years of independent journalism.

  1. Science & Tech
  2. Coronavirus
21 May 2020updated 06 Oct 2020 9:45am

US government commits $1.2bn to Oxford vaccine development, orders 300 million doses

By Samuel Horti

The US government will pump up to $1.2bn (£980m) into the development of AstraZeneca and the University of Oxford’s coronavirus vaccine, it has announced.

The US will also order 300 million doses of the vaccine once production begins, it said.

The news comes after AstraZeneca said it had the capability to produce one billion doses of the vaccine this year, and that it would begin supplying 100 million doses to the UK government in September, provided clinical trials prove successful.

In a statement, the company acknowledged that the vaccine might not work, but said it was ready to facilitate trials in several countries if early UK trials showed positive results.

It also said it would work with the World Health Organisation to ensure the vaccine was distributed fairly around the globe.

Sign up for The New Statesman’s newsletters Tick the boxes of the newsletters you would like to receive. Quick and essential guide to domestic and global politics from the New Statesman's politics team. The New Statesman’s global affairs newsletter, every Monday and Friday. The best of the New Statesman, delivered to your inbox every weekday morning. A handy, three-minute glance at the week ahead in companies, markets, regulation and investment, landing in your inbox every Monday morning. Our weekly culture newsletter – from books and art to pop culture and memes – sent every Friday. A weekly round-up of some of the best articles featured in the most recent issue of the New Statesman, sent each Saturday. A weekly dig into the New Statesman’s archive of over 100 years of stellar and influential journalism, sent each Wednesday. Sign up to receive information regarding NS events, subscription offers & product updates.
I consent to New Statesman Media Group collecting my details provided via this form in accordance with the Privacy Policy